Biogen's Alzheimer's Drug Coverage Limited by U.S.

The video discusses Biogen's controversial Alzheimer's drug and Medicare's decision to limit its coverage to participants in randomized control trials. This decision is based on concerns about the drug's potential harm and lack of conclusive evidence of its effectiveness. The discussion highlights the implications for the drug's market and the ongoing controversies in the Alzheimer's community.

What are the potential risks associated with the drug as mentioned in the discussion?

What does the controversy surrounding the drug indicate about the Alzheimer's community's views?